SCHEMBL22316554

SCHEMBL22316554

CCOC(=O)C(CC(=O)OI)NC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 2/20 0.36
GAA P10253 2/20 0.36
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
POLB P06746 1/20 0.36
CAD P27708 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
PKM P14618 2/20 0.32
MMP8 P22894 1/20 0.32
CPB2 Q96IY4 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TRPA1 O75762 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27400834 0.88 GAA (0.45) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL27400841 0.88 GAA (0.45) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL21282543 0.88 GAA (0.45) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL22316053 0.84 L3MBTL1 (0.50) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL22316496 0.81 TGFBR1 (0.31)
SCHEMBL27400855 0.81 CAD (0.38) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL27400849 0.81 CAD (0.38) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL27400846 0.76 GAA (0.43) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL27400858 0.76 GAA (0.43) L3MBTL1CYP1A2CYP2C9CYP2C19HTT
SCHEMBL27400826 0.75 L3MBTL1 (0.63) L3MBTL1CYP1A2CYP2C9CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
US-20200247845-A1 Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247845-A1 Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same FCGRT, QARS1, INHA L3MBTL1 4119/4885CYP1A2 147/4885CYP2C9 1067/4885
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same FCGRT, QARS1, INHA L3MBTL1 4119/4885CYP1A2 147/4885CYP2C9 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.